COGNI: Cognitive Function and Health-related Quality of Life After Neuro-intensive Care

Sponsor
Rigshospitalet, Denmark (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04881097
Collaborator
Aalborg University Hospital (Other), Aarhus University Hospital (Other), Odense University Hospital (Other)
486
48

Study Details

Study Description

Brief Summary

The study will provide information on cognitive impairment and Health related quality of life in patients surviving 12 months after acute brain injury, generate a hypothesis of useful variables to predict cognitive impairment or low levels of HRQoL, and potentially inform interventions for the prevention and treatment of cognitive impairment following neuro-ICU stay.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: no intervention

Detailed Description

The aim is to 1) measure the frequency and extent of cognitive impairment after acute brain injury at six and 12-months after neuro-Intensive care unit (ICU) admission 2) explore the association between cognitive impairment at six and 12 months after ICU admission with the following potential risk factors: duration of ICU delirium (days), duration of sepsis (days), duration of post traumatic amnesia (days) and the severity of brain injury (initial Glasgow Coma Scale , 3) describe Health related quality of life, functional disability and frailty at six and 12 after ICU admission and 4) explore the association between the functional disability, frailty and health-related quality of life at 12 months after ICU admission

Study Design

Study Type:
Observational
Anticipated Enrollment :
486 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Cognitive Function and Health-related Quality of Life After Neuro-intensive Care: An Observational Multicenter Cohort Study
Anticipated Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Change in Global cognitive function [from baseline to 6 months after ICU admission]

    measured by The Repeatable Battery for the Assessment of Neuropsychological Status, Overall score (mean 100; SD=15). Higher scores indicate better cognitive functioning.

  2. Change in Global cognitive function [from baseline to 12 months after ICU admission]

    measured by The Repeatable Battery for the Assessment of Neuropsychological Status, Overall score (mean 100; SD=15). Higher scores indicate better cognitive functioning.

  3. Change in Executive function [from baseline to 6 months after ICU admission]

    measured by Trail Making Test B, Score indicate time in seconds to complete task, the higher speed (less seconds) indicates higher executive function

  4. Change in Executive function [from baseline to 12 months after ICU admission]

    measured by Trail Making Test B, Score indicate time in seconds to complete task, the higher speed (less seconds) indicates higher executive function

Secondary Outcome Measures

  1. Change in Health related quality of life after brain injury [from baseline to 6 months after ICU admission]

    measured with a disease specific questionnaire:Quality of Life after Brain Injury overall scale (QOLIBRI-OS). Scores are from 0-100, the higher the score the more quality of life.

  2. Change in Health related quality of life after brain injury [from baseline to 12 months after ICU admission]

    measured with a disease specific questionnaire:Quality of Life after Brain Injury overall scale (QOLIBRI-OS). Scores are from 0-100, the higher the score the more quality of life.

  3. Delirium [during the procedure (ICU stay) up to 30 days]

    measured by Confusion measured by CAM-ICU or Intensive Care Delirium Screening Checklist (ICDSC).

  4. Change in Disability after head injury/nontraumatic acute brain insults I [from baseline to 6 months after ICU admission]

    measured by Glasgow outcome scale extended (GOSE). Scores from 1 to 8, higher scores indicate less disability

  5. Change in Disability after head injury/nontraumatic acute brain insults I [from baseline to 12 months after ICU admission]

    measured by Glasgow outcome scale extended (GOSE). Scores from 1 to 8, higher scores indicate less disability

  6. Change in Disability after head injury/nontraumatic acute brain insults II [from baseline to 6 months after ICU admission]

    measured by Extended disability rating scale (DRS). Scores from 0 to 29, the higher the score the more disability

  7. Change in Disability after head injury/nontraumatic acute brain insults II [from baseline to 12 months after ICU admission]

    measured by Extended disability rating scale (DRS). Scores from 0 to 29, the higher the score the more disability

  8. Change in Frailty [baseline to 6 months after ICU admission]

    measured by the Clinical Frailty Scale (CFS). Scale is from 1 to 9 ( the higher score the more frail).

  9. Change in Frailty [baseline to 12 months after ICU admission]

    measured by the Clinical Frailty Scale (CFS). Scale is from 1 to 9 ( the higher score the more frail).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 110 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Traumatic brain injury

  • Spontaneous intracranial hemorrhage

  • Ischemic stroke

  • An anticipated stay in the neuro-ICU for 48 hours or longer.

Exclusion Criteria:
  • Persistent coma defined as Richmond Agitation-Sedation Scale (RASS) -5 to -3 throughout the neuro-ICU stay

  • Congenital brain injury

  • Suspected pre-existing Cognitive impairment (Informant Questionnaire on cognitive decline in the elderly (IQCODE): 3.3 or more) (regardless of cause)

  • Permanent residence outside Denmark

  • Inability to communicate in Danish

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Rigshospitalet, Denmark
  • Aalborg University Hospital
  • Aarhus University Hospital
  • Odense University Hospital

Investigators

  • Principal Investigator: Suzanne F Herling, Ph.D, Rigshospitalet, Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kirsten Moller, Professor, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT04881097
Other Study ID Numbers:
  • NNF 20OC0064760
First Posted:
May 11, 2021
Last Update Posted:
May 11, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kirsten Moller, Professor, Rigshospitalet, Denmark
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 11, 2021